• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Study finds sucralose produces previously unidentified metabolites

Bioengineer by Bioengineer
August 27, 2018
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Sucralose, a widely used artificial sweetener sold under the trade name Splenda®, is metabolized in the gut, producing at least two fat-soluble compounds, according to a recent study using rats. The finding differs from the studies used to garner regulatory approval for sucralose, which reported that the substance was not broken down in the body. The new study also found that sucralose itself was found in fatty tissues of the body.

The researchers used the same experimental model used by the Food & Drug Administration (FDA) to assess the safety of foods based on accepted daily intake. In this case, that involved administering an average dose of 80.4 milligrams/kilogram/day to 10 rats for 40 days. Urine and feces from the rats were collected and assessed for those 40 days, and for the following two weeks. At the end of the two-week follow-up period, fatty tissue from a subset of the rats was also tested.

The researchers, from North Carolina State University and Avazyme Inc. – an analytical testing company – used techniques designed to detect both fat- and water-soluble metabolites. That's significant because industry did not use state-of-the-art techniques that targeted the full suite of fat-soluble metabolites in the studies it submitted to the FDA when seeking FDA approval for sucralose.

"Our techniques were more suited to extracting and preserving fat-soluble metabolites," says Susan Schiffman, an adjunct professor at NC State and co-author of the recent study. "We were also able to use state-of-the-art analytical techniques to identify those metabolites.

"We found two metabolites in urine and feces throughout the sucralose dosing period," Schiffman says. "Those metabolites could still be detected in the urine 11 days after we stopped giving the rats sucralose, and six days after the sucralose itself could no longer be detected. That's particularly interesting, given that the metabolism studies that the FDA's approval were based on reported that ingested sucralose was not metabolized."

Specifically, the metabolites were acetylated compounds, which are highly lipophilic – meaning they are easily dissolved in fat. That means they are more likely to stick around in the body.

In addition, the researchers found that sucralose itself was detected in the adipose, or fatty, tissues of rats two weeks after the rats had stopped receiving sucralose.

"Based on previous studies, we know that sucralose can be passed on by nursing mothers in their breastmilk," Schiffman says. "And, among other findings, we know that sucralose can reduce the abundance of beneficial bacteria in the gut. Our new study shows that sucralose is also creating metabolites whose potential health effects we know little or nothing about.

"As a result, we feel that it may be time to revisit the safety and regulatory status of sucralose," Schiffman says.

###

The paper, "Intestinal Metabolism and Bioaccumulation of Sucralose In Adipose Tissue In The Rat," is published in the Journal of Toxicology and Environmental Health, Part A. The paper was co-authored by Volker Bornemann and Stephen Werness of Avazyme; and Lauren Buslinger, director of veterinary services for laboratory animal resources in NC State's College of Veterinary Medicine. This research was supported by the Engineering Foundation at North Carolina State University.

Media Contact

Matt Shipman
[email protected]
919-515-6386
@NCStateNews

Why Not Us?

https://news.ncsu.edu/2018/08/sucralose-metabolites/

Related Journal Article

http://dx.doi.org/10.1080/15287394.2018.1502560

Share12Tweet8Share2ShareShareShare2

Related Posts

New Study Uncovers Mechanism Behind Burn Pit Particulate Matter–Induced Lung Inflammation

New Study Uncovers Mechanism Behind Burn Pit Particulate Matter–Induced Lung Inflammation

February 6, 2026

DeepBlastoid: Advancing Automated and Efficient Evaluation of Human Blastoids with Deep Learning

February 6, 2026

Navigating the Gut: The Role of Formic Acid in the Microbiome

February 6, 2026

AI-Enhanced Optical Coherence Photoacoustic Microscopy Revolutionizes 3D Cancer Model Imaging

February 6, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Scientists Identify SARS-CoV-2 PLpro and RIPK1 Inhibitors Showing Potent Synergistic Antiviral Effects in Mouse COVID-19 Model

Neg-Entropy: The Key Therapeutic Target for Chronic Diseases

Multidisciplinary Evidence-Based Guidelines for Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.